Homology Medicines, Inc., a Lexington, Massachusetts-based newly formed genetic medicines company, closed a $43.5m Series A financing.
The round was co-led by 5AM Ventures and Arch Venture Partners with participation from Temasek, Deerfield Management, and ARCH Overage Fund.
Led by Arthur Tzianabos, Ph.D., Chief Executive Officer, Sam Rasty, Ph.D., Chief Operating Officer, and Albert Seymour, Ph.D. Chief Scientific Officer, Homology focused on translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases.
The company, founded and incubated with a seed investment within the 4:59 Initiative, the creation engine of 5AM Ventures, is based on science that harnesses the naturally occurring process of homologous recombination. Homology obtained an exclusive worldwide license to this technology platform, which is based on the research of Saswati Chatterjee, Ph.D., Department of Surgery, member of the Beckman Research Institute at the City of Hope in California and co-founder and Chair of Homology’s Scientific Advisory Board.
The Homology Board of Directors consists of Dr. Tzianabos, tKush Parmar, M.D., Ph.D., Managing Partner at 5AM Ventures; Steven Gillis, Ph.D., Managing Director with ARCH Venture Partners, and Richard Gregory, Ph.D., Executive Vice President and Chief Scientific Officer of ImmunoGen.